David Roman

Larry Biegelsen

Matt O'Brien

Mike Polark

Rick Wise

Stephanie Piazzola

- Kestra Medical Technologies reported **Q1 2026 revenue of $19.4 million**, a **52%** increase year-over-year, driven by a **51%** increase in prescriptions accepted to **4,200**.  **[1877184_2139411_1]** **[1877184_2139411_4]**  Gross margin expanded to **45.7%**, marking the seventh consecutive quarter of expansion.  **[1877184_2139411_1]** **[1877184_2139411_4]** 
- The company updated its fiscal year 2026 revenue guidance to **$88 million**, an increase of **47%** compared to fiscal year 2025, up from the prior guidance of **$85 million**.  **[1877184_2139411_4]** 
- Operational improvements include the percentage of fittings for patients with in-network benefits now approaching **80%**, up from **70%** six months prior, and the conversion rate improving to approximately **47%** in Q1 2026 from **40%** in the prior year period.  **[1877184_2139411_2]** **[1877184_2139411_4]** 
- Enrollment has concluded for the FDA post-approval study, which is expected to include **24,000-25,000 patients** and will be presented at the American Heart Association Scientific Sessions in November.  **[1877184_2139411_2]** **[1877184_2139411_11]**

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY 2026 Revenue Guidance

- Kestra Medical Technologies (KMTS) reported strong Q1 2026 results with **revenue growing 52% year-over-year to $19.4 million** and accepted prescriptions increasing **51% year-over-year to over 4,200**.  **[1877184_2139391_1]** **[1877184_2139391_4]** 
- The company achieved its **seventh consecutive quarter of gross margin expansion**, reaching **45.7%** in Q1 2026, up from **32.9%** in the prior year period, and expects to reach **70% plus** gross margins in the future.  **[1877184_2139391_1]** **[1877184_2139391_2]** **[1877184_2139391_4]** 
- KMTS updated its **fiscal year 2026 revenue guidance to $88 million**, representing a **47% increase** compared to fiscal year 2025, up from the prior guidance of **$85 million**.  **[1877184_2139391_4]** 
- The percentage of fittings for patients with in-network benefits is now approaching **80%**, up from **70%** six months ago, contributing to an improved conversion rate of approximately **47%** in Q1 2026.  **[1877184_2139391_2]** **[1877184_2139391_4]** 
- As of July 31, 2025, cash and cash equivalents totaled **$201.2 million**.  **[1877184_2139391_4]**

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY26 Revenue Guidance

- Kestra Medical Technologies reported **Q1 fiscal 2026 revenue of $19.4 million**, representing a **52% increase** year-over-year, driven by a **51% year-over-year increase in prescriptions** accepted for the Assure system.  **[1877184_2139167_1]** **[1877184_2139167_4]** 
- Gross margin for Q1 2026 was **45.7%**, compared to **32.9%** in the prior year period, marking the seventh consecutive quarter of gross margin expansion.  **[1877184_2139167_1]** **[1877184_2139167_4]** 
- The company updated its fiscal year 2026 revenue guidance to **$88 million**, an increase of **47%** compared to fiscal year 2025, which is up from the prior guidance of $85 million.  **[1877184_2139167_4]** 
- Cash and cash equivalents totaled **$201.2 million** as of July 31, 2025.  **[1877184_2139167_4]** 
- Kestra achieved a major clinical milestone with the conclusion of enrollment in its FDA post-approval study, which is expected to include between **24,000 and 25,000 patients** and will be presented at the American Heart Association Scientific Sessions in November.  **[1877184_2139167_2]** **[1877184_2139167_3]** **[1877184_2139167_10]**

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY26 Guidance

- Kestra Medical Technologies, Ltd. reported **revenue of $19.4 million** for the first quarter of fiscal 2026, which ended July 31, 2025, representing a **52% increase** compared to the prior year period.  **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:0]** 
- The company's **gross margin expanded to 45.7%** in Q1 FY26, up from 32.9% in the prior year period.  **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:0]** 
- Kestra Medical Technologies, Ltd. **increased its fiscal year 2026 revenue guidance to $88 million**, reflecting **47% growth** compared to FY25.  **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:0]** 
- The **GAAP net loss and comprehensive loss for Q1 FY26 was $25.8 million**.  **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:0]** **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:3]** 
- As of July 31, 2025, **cash and cash equivalents totaled $201.2 million**.  **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:0]** **[1877184_0000950170-25-114228_ck0001877184-ex99_1.htm:4]**

KESTRA MEDICAL TECHNOLOGIES (KMTS)